Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C1570
http://purl.obolibrary.org/obo/NCIT_C1570
Preferred Name

Dinutuximab
Definitions
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
prefLabel
Dinutuximab
label
Dinutuximab
PDQ_Closed_Trial_Search_ID
42042
code
C1570
Has_Target
prefixIRI
NCIT:C1570
in_subset
Display_Name
Dinutuximab
Preferred_Name
Dinutuximab
FDA_UNII_Code
7SQY4ZUD30
Contributing_Source
CTRP
FDA
PCDC
Maps_To
Dinutuximab
CAS_Registry
1363687-32-4
NSC Number
623408
NCI_Drug_Dictionary_ID
42042
Legacy Concept Name
Monoclonal_Antibody_Ch14_18
type
ALT_DEFINITION
A substance being studied in the treatment of cancer. It binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. It is a type of monoclonal antibody.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
42042
Accepted_Therapeutic_Use_For
childhood neuroblastoma
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C3871452
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display